# EDGAR Filing Document

**Accession Number:** 0001472012
**File Stem:** 0001104659-23-001705
**Filing Date:** 2023-1
**Character Count:** 20314
**Document Hash:** a4f70e791c862e2582aeeddb98020d82
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-001705.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001104659-23-001705

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230104

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immunome Inc.
- **CENTRAL INDEX KEY:** 0001472012
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770694340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39580
- **FILM NUMBER:** 23513785

**BUSINESS ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341
- **BUSINESS PHONE:** 610-321-3700

**MAIL ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

------

**FORM 8-K**

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): January 4, 2023**

------

**Immunome, Inc.**

**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39580** | **77-0694340** |
| **(state or other jurisdiction <br> of incorporation)** | **(Commission <br> File Number)** | **(I.R.S. Employer <br> Identification No.)** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**665 Stockton Drive, Suite 300 <br> Exton, Pennsylvania** | &nbsp;&nbsp;**19341** |
| &nbsp;&nbsp;**(Address of principal executive offices)** | &nbsp;&nbsp;**(Zip Code)** |

---

**Registrant's telephone number, including area code: (610** **) 321-3700**

**Not applicable**

**(Former name or former address, if changed since last report.)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange<br> on which registered |
| **Common Stock, $0.0001 par value per share** **IMNM** | **The Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 1.01. Entry into a Material Definitive Agreement.**

On January 4, 2023, Immunome, Inc. (the "**Company**") entered into a collaboration and option agreement ("**Collaboration Agreement**") with AbbVie Global Enterprises Ltd. ("**AbbVie**"), pursuant to which the Company will use its proprietary discovery engine to discover and validate targets derived from patients with three specified tumor types, and antibodies that bind to such targets, which may be the subject of further development and commercialization by AbbVie. The research term is at least 66 months, subject to extension in certain circumstances by specified extension periods. Pursuant to the terms of the Collaboration Agreement, with respect to each novel target-antibody pair that the Company generates that meets certain mutually agreed criteria (each, a "**Validated Target Pair**" or "**VTP**"), the Company granted to AbbVie an exclusive option (up to a maximum of 10 in total) to purchase all rights in and to such Validated Target Pair, for all human and non-human diagnostic, prophylactic and therapeutic uses throughout the world, including without limitation the development and commercialization of certain products derived from the assigned Validated Target Pair and directed to the target comprising such VTP ("**Products**"). No rights are granted by Company to AbbVie under any of Company's platform technology covering the Company's discovery engine. Until the expiration of the research term, the Company is not permitted to conduct any activities in connection with targets or antibodies derived from patients with the specified tumor types, whether independently or with other third parties, except in limited circumstances with respect to certain target-antibody pairs that are no longer subject to the collaboration with AbbVie. In addition, during the term of the Collaboration Agreement, the Company is not permitted to develop products directed to targets that are included in VTPs purchased by AbbVie, or to which AbbVie still has rights under the Collaboration Agreement, whether independently or with other third parties.

Under the Collaboration Agreement, AbbVie will pay the Company an upfront payment of $30 million, plus certain additional platform access payments in the aggregate amount of up to $70 million based on the Company's use of its discovery engine in connection with activities under each stage of the research plan, and delivery of VTPs to AbbVie. AbbVie will also pay an option exercise fee in the low single digit millions for each of the up to 10 VTPs for which it exercises an option. If AbbVie progresses development and commercialization of a Product, AbbVie will pay the Company development and first commercial sale milestones of up to $120 million per target, and sales milestones based on achievement of specified levels of net sales of Products of up to $150 million in the aggregate per target, in each case, subject to specified deductions in certain circumstances. On a Product-by-Product basis, AbbVie will pay the Company tiered royalties on net sales of Products at a percentage in the low single digits, subject to specified reductions and offsets in certain circumstances. AbbVie's royalty payment obligation will commence, on a Product-by-Product and country-by-country basis, on the first commercial sale of such Product in such country and will expire on the earlier of (a) (i) the ten (10)-year anniversary of such first commercial sale for such Product in such country, or (ii) solely with respect to a Product that incorporates an antibody comprising a VTP (or certain other antibodies derived from such delivered antibody), the expiration of all valid claims of patent rights covering the composition of matter of any such antibody (whichever out of (i) or (ii) is later), and (b) the expiration of regulatory exclusivity for such Product in such country.

The Collaboration Agreement will expire upon the expiration of the last to expire royalty payment obligation with respect to all Products in all countries, subject to earlier expiration if all option exercise periods for all Validated Target Pairs expire without AbbVie exercising any option. In addition, the research term will terminate if AbbVie does not elect to make certain platform access payments at specified points during the research term, in order for the Company to continue the target discovery activities under the collaboration. The Collaboration Agreement may be terminated by (a) either party upon the other party's uncured material breach, or upon any insolvency event of the other party, (b) AbbVie for convenience upon a specified period prior written notice, or (c) AbbVie for the Company's breach of representations and warranties with respect to debarment or compliance with anti-bribery and anti-corruption laws. If AbbVie has the right to terminate the Collaboration Agreement for the Company's uncured material breach or a breach of representations and warranties with respect to debarment or compliance with anti-bribery and anti-corruption laws, AbbVie may elect to continue the Collaboration Agreement, subject to certain specified reductions applicable to certain of AbbVie's payment obligations (with a specified floor on such reductions).

The foregoing description of the Collaboration Agreement is not complete and is subject to, and is qualified in its entirety by reference to, the full text of the Collaboration Agreement. A copy of the Collaboration Agreement will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2022. The Company intends to seek confidential treatment for certain portions of the Collaboration Agreement pursuant to a Confidential Treatment Request submitted to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

---

| | |
|:---|:---|
| **Item 7.01** | **Regulation FD Disclosure.** |

---

On January 6, 2023, Immunome and AbbVie issued a joint press release titled "AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets," a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information contained herein and in Exhibit 99.1 attached hereto shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits**. |

---

(d) ---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| [99.1](tm231749d2_ex99-1.htm) | [Joint press release issued by the Company and AbbVie on January 6, 2023 titled "AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets"](tm231749d2_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Immunome, Inc.** | **Immunome, Inc.** | **Immunome, Inc.** |
| Date: | January 6, 2023 | By: |  | /s/ Purnanand D. Sarma, Ph.D. |
|  |  |  | Name: | Purnanand D. Sarma, Ph.D. |
|  |  |  | Title: | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm231749d2_ex99-1img002.jpg)

**PRESS RELEASE**

**AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets**

*- Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine*

*- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties*

**NORTH CHICAGO, Ill, and EXTON, Pa., January 6, 2023** – AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine.

"Partnering with Immunome represents AbbVie's commitment to developing and commercializing novel treatment approaches for solid tumors," said Steve Davidsen, Ph.D., vice president, oncology discovery research, AbbVie. "Immunome's approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates. We look forward to utilizing their Discovery Engine to enhance our existing oncology pipeline."

"This collaboration with AbbVie, a true leader in the development and commercialization of oncology therapeutics, demonstrates the strength of Immunome's Discovery Engine," said Purnanand Sarma, Ph.D., president and CEO of Immunome. "AbbVie shares our vision of harnessing the power of the human immune response to yield novel and first-in-class therapeutics that represent a shift in the cancer discovery paradigm. We are delighted to be working with AbbVie and look forward to leveraging their vast development and commercialization expertise in bringing new therapies to patients suffering from life-threatening cancers. This collaboration fits well within Immunome's strategy to maximize the new drug discovery potential of our Discovery Engine through partnerships across multiple therapeutic segments, in addition to advancing our own proprietary pipeline."

Under the terms of the agreement, Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from the selected tumors. Immunome will receive an upfront payment of $30M and will be eligible to receive additional platform access payments in the aggregate amount of up to $70M based on AbbVie's election for Immunome to continue research using its Discovery Engine. Immunome is also eligible to receive development and first commercial sale milestones of up to $120M per target with respect to certain products derived from target-antibody pairs that AbbVie elects to purchase, with potential for further sales-based milestones as well as tiered royalties on global sales.

![](tm231749d2_ex99-1img002.jpg)

**About AbbVie**

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at <u>www.abbvie.com</u>. Follow @abbvie on <u>Twitter</u>, <u>Facebook</u>, <u>Instagram</u>, <u>YouTube</u> and <u>LinkedIn</u>

**About Immunome**

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initial focus is on discovering and developing therapeutics in oncology internally and in collaboration with our partners. For more information, please visit <u>www.immunome.com</u> or follow us on <u>Twitter</u> and <u>LinkedIn</u>.

**About Immunome's Discovery Engine**

Immunome's proprietary Discovery Engine identifies novel therapeutic antibodies and their targets by leveraging memory B cells, highly educated components of the immune system, isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome's Discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel targets. The functional data we generate differentiates our approach from those that use deep sequencing of B cells to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility.

![](tm231749d2_ex99-1img002.jpg)

**Forward-Looking Statements**

This press release includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome's beliefs and expectations regarding, among other things: Immunome's and its collaborators' ability to achieve anticipated discovery, development and commercial milestones the timing and results of preclinical studies and clinical trials; clinical plans; general regulatory actions; translation of preclinical data into clinical safety and efficacy; and therapeutic potential and benefits of, and possible need and demand for, product candidates that are not historical fact. Forward-looking statements may be identified by the words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "suggest," "can," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on Immunome's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the fact that research and development data are subject to differing interpretations and assessments; Immunome's ability to execute on its strategy, including collaborations with third parties, including with respect to its R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the effectiveness of Immunome's product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates and that further variants of concern could emerge; Immunome's ability to fund operations and raise capital; Immunome's reliance on vendors; Immunome's relationships with its collaborators; the competitive landscape; the impact of the COVID-19 pandemic on Immunome's business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 28, 2022, and elsewhere in Immunome's other filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. In this press release, we may discuss our current and potential future product candidates that have not yet completed clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority, including expectations about their therapeutic potential and benefits thereof. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied.

###

![](tm231749d2_ex99-1img002.jpg)

**Contacts:**

**<u>AbbVie</u>**

**Media**

Frank Benenati

(847) 938-8745

**Investors**

Liz Shea

(847) 935-2211

**<u>Immunome:</u>**

**Media**

Gwen Schanker

Account Supervisor

LifeSci Communications

gschanker@lifescicomms.com

**Investors** 

Laurence Watts

Managing Director

Gilmartin, LLC

laurence@gilmartinir.com